A*Star

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to  develop a point-of-care diagnostic platform for infectious disease.

The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.  

The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.

The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.

Researchers from A*Star and elsewhere have implicated a recessive mutation in CAMK2A in a neurodevelopmental disorder affecting a pair of siblings.

The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.